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1078–5884/00Long-term Treatment of Deep Venous Thrombosis
with a Low Molecular Weight Heparin (Tinzaparin):
A Prospective Randomized Trial
M.E. Daskalopoulos,1,2* S.S. Daskalopoulou,1 E. Tzortzis,1 P. Sfiridis,2 A. Nikolaou,1
D. Dimitroulis,1 I. Kakissis1 and C.D. Liapis11Department of Vascular Surgery, Athens University Medical School and 2Vascular Unit,
1st IKA Hospital of Athens, Athens, GreeceObjectives. Evaluation of the effectiveness and safety of the low molecular weight heparin (LMWH) tinzaparin versus
unfractionated heparin (UFH) followed by acenocoumarol in proximal deep venous thrombosis (DVT).
Design. Prospective, randomized clinical trial.
Material and methods. Consecutive patients (nZ108) with acute leg DVT, confirmed by duplex, were randomized to
either tinzaparin alone or UFH and acenocoumarol for 6 months. Patients were evaluated ultrasonographically at entry, 1,
3, 6 and 12 months. Thrombus regression, reflux distribution and the incidence of complications were studied. A cost-
analysis, comparing the two treatments, was performed.
Results. The overall incidence of major events (mortality, DVTrecurrence, pulmonary embolism, major bleeding, heparin-
induced thrombocytopenia) was significantly different (pZ0.035) in favor of tinzaparin (7 versus 17 events). The
ultrasonographic clot volume score (an index of recanalization) decreased significantly in both treatment groups. However,
tinzaparin produced significantly more extended overall recanalization from 3 months onwards (p!0.02). Thrombus
regression was equivalent or in favor of tinzaparin in the different DVTsubgroups and venous segments, but the statistical
significance varied. Reflux showed non-significant differences overall or in subgroups. A cost-analysis resulted in favor of
LMWH.
Conclusions. A fixed daily dose of tinzaparin for 6 months was at least as effective and safe as UFH and acenocoumarol.
Regarding major events and recanalization, there was a significant benefit in favor of tinzaparin. Long-term DVT treatment
with tinzaparin could represent an alternative to conventional treatment.Keywords: Venous thromboembolism; Low molecular weight heparin; Oral anticoagulants; Duplex scanning; Recanaliza-
tion; Reflux.Introduction
Unfractionated heparin (UFH) remains the mainstay
of both initial therapy and prevention of acute venous
thromboembolic events (VTE). In recent years, low
molecular weight heparins (LMWHs) have been
widely tested in several studies versus UFH in the
initial treatment of deep venous thrombosis (DVT).
Meta-analyses of these studies have indicated that
LMWHs prevent thrombus growth to a greater extent
than UFH and suggest their superiority over UFH in
preventing recurrent VTE.1,2
Currently, most patients with acute VTE events areing author. Marios Margaritis Daskalopoulos, 109,
., GR-115 24 Athens, Greece.
: mdaskalopoulos@hotmail.com
0638 + 13 $35.00/0 q 2005 Elsevier Ltd. All rights resertreated with full doses of UFH or LMWH followed by
at least 3 months of oral anticoagulation. Although
oral anticoagulants (OAs) are the most widely used
form of long-term treatment for patients with VTE,
there are always concerns about hemorrhagic risks
and patients’ compliance with coumarin therapy.
Certain DVT patients, such as the elderly3 and patients
with cancer,4 are prone to treatment complications. In
addition, OAs are contraindicated for pregnant
women since coumarin derivatives cross the placenta
and carry a significant risk of central nervous system
abnormalities in the fetus.5 Furthermore, treatment
with vitamin K antagonists requires strict laboratory
control and consequent adjustment of the drug
dosage. Finally, OA therapy is not always effective
enough to prevent VTE recurrence6 or the develop-
ment of post-thrombotic syndrome in the long-term.Eur J Vasc Endovasc Surg 29, 638–650 (2005)
doi:10.1016/j.ejvs.2004.02.029, available online at http://www.sciencedirect.com onved.
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effective and safe as UFH when administered by
fixed-dose subcutaneous injections, suggested that it
might be possible to use LMWH preparations to treat
patients with DVT at home.7–9 Due to their pharma-
cokinetic properties10 (longer plasma half-life,
improved subcutaneous bioavailability and less varia-
bility in response to fixed doses), a stable and
sustained anticoagulant effect is achieved when these
medications are administered subcutaneously once or
twice daily, with no need for laboratory monitoring.11
Moreover, they are associated with lower rate of
heparin-induced thrombocytopenia (HIT).12 Outpati-
ent DVT treatment with LMWHs has been extensively
tested in a number of prospective studies13–15 support-
ing its feasibility and safety. This trend has become
daily clinical practice in many countries and is now
recommended in the most recent international
guidelines.16
Some recent and ongoing research evaluates the
efficacy and safety of LMWH therapy as an alternative
to OAs in the long-term management of VTE. During
the last decade, eight randomized trials have been
published challenging this hypothesis.17–24 When the
results of these studies are considered collectively, a
significant decrease is documented in the rates of
major or minor bleeding complications in patients
assigned to therapy with LMWHs.25 These findings
suggest that LMWHs could be an alternative to oral
anticoagulants in subjects at risk of bleeding as well as
in those who cannot have periodic laboratory moni-
toring, such as patients who live in geographically
remote areas, or are unable or reluctant to undergo
regular monitoring. Nevertheless, there are questions
still to be answered. Do LMWHs perform better than
OAs in the resolution of thrombi? Do they prevent
deep vein valve insufficiency after a thrombotic event?
And finally, is LMWH therapy more effective in terms
of cost and sparing of health care resources?MethodsStudy design
We conducted an open-label prospective randomized
clinical study to compare the LMWH tinzaparin
sodium (Innohep/Leo Pharmaceutical Products Ltd.,
Ballerup, Denmark) administered subcutaneously
once daily in a weight-adjusted dose of 175 anti Xa
IU/Kg bodyweight for a period of 6 months, with
conventional antithrombotic therapy (UFH followed
by OAs) for a similar period of time. Primary outcomeevents were the recanalization of the thrombosed
veins, expressed by the reduction of a quantitative
ultrasonographic score, as well as the development of
reflux in the affected veins during the study period.
The overall incidence of major events was also
considered. Secondary endpoints were the develop-
ment of objectively documented recurrent VTE (recur-
rent DVT and pulmonary embolism (PE)) and the
incidence of major and minor hemorrhagic compli-
cations and mortality throughout the study period.
The study protocol was designed in accordance
with the principles of the Helsinki–Tokyo declaration
and was reviewed and approved by the Scientific and
Ethics Committee of the recruitment Institution.
Eligible patients were provided with an information
sheet and written consent was obtained. The study
population was randomized by means of a computer
schedule.Patients
Consecutive symptomatic adult patients (aged over 18
years), that had been referred to the Accident and
Emergency Department of a district hospital with
acute proximal DVT of the lower limbs (onset of
symptoms less than 1 week) were eligible for entering
the study. The thrombotic process had to be objectively
documented by means of color duplex ultrasound
scan. Patients meeting the conditions listed in Table 1
were excluded from the study.Therapeutic regimens
Patients assigned to the conventional therapy group
received an intravenous bolus of 5000 IU UFH
(Heparin/Leo Pharmaceutical Products Ltd., Ballerup,
Denmark) immediately upon admission to the ward.
From the various protocols used for intravenous UFH
infusion, we adhered to the one proposed by Cruick-
shank et al.26 This was followed by a continuous
intravenous UFH infusion for 5–7 days. The activated
partial thromboplastin time (APTT) was measured
4 hours after initiation of heparin administration and
was repeated at intervals of 6 hours thereafter, to reach
the therapeutic range (ratio: 1.5–2.5). APTT values
were obtained at least once daily during intravenous
UFH administration and the dose was adjusted
accordingly. Oral anticoagulation therapy with aceno-
coumarol (Sintrom/Novartis Pharma AG, Basle, Swit-
zerland) was commenced on the third day following
UFH therapy. The dose of the drug was adjusted
aiming at an international normalized ratio (INR)
between 2.0 and 3.0. At the same time patients wereEur J Vasc Endovasc Surg Vol 29, June 2005
Table 1. Exclusion criteria according to the study protocol
Exclusion criteria
1 Segmental deep venous thrombosis restricted to infrapopliteal deep veins or calf muscles as determined by duplex ultrasonography
2 Symptomatic or clinically suspected pulmonary embolism
3 History of recently diagnosed (within 12 months) deep venous thrombosis or pulmonary embolism
4 Patient already under anticoagulant therapy
5 Bleeding tendency objectively confirmed
6 Hypersensitivity to heparin preparations or coumarin derivatives
7 Uncontrolled hypertension
8 History of recently diagnosed (less than 1 month) cerebrovascular accident
9 Intracranial artery aneurysm
10 Infectious endocarditis
11 Thrombocytopenia (platelet count!100,000/mm3)
12 Active peptic ulcer
13 Hepatic or renal failure
14 History of asthma
15 Recent spinal or epidural anesthesia or intraspinal paracentesis (less than 5 days)
16 Recent surgery (less than 5 days)
17 Recently performed thrombolysis or under antiplatelet therapy
18 Body weight less than 35 Kg
19 Pregnancy
20 Illicit drug addiction
21 Altered mental status or impaired cognitive function with inability to comply with study protocol
M. E. Daskalopoulos et al.640encouraged to ambulate wearing elastic support
stockings. As a rule, UFH treatment was discontinued
as soon as the INR value reached 2.0 or more. After
discharge patients were instructed to attend the
vascular outpatient clinic at the protocol time intervals
predefined by the study.
Patients allocated to receive treatment with LMWH
underwent no hospitalization at all. They received a
subcutaneous injection of tinzaparin sodium in a
weight-adjusted dose (175 anti Xa IU/Kg). They
attended a short course by a vascular nurse regarding
the administration technique. After the patients and
their relatives were adequately instructed on how to
perform subcutaneous injections, they were allowed to
leave the hospital. Tinzaparin sodium was prescribed
as a single subcutaneous weight-adjusted standard
dose without laboratory monitoring, for 6 months.
According to the study protocol, LMWH patients were
also instructed to attend the vascular outpatient clinic
as the OA patients.Assessment of the patients
The assessment of all patients included past medical
history, clinical examination, blood tests and color
duplex imaging.
A detailed history was obtained prior to any
examination. A special four-page form was filled in,
briefing the most important information for every
patient.
Clinical examination was aiming to identify the
presence or absence and the extent of venous
thrombosis in the symptomatic leg. Moreover, inEur J Vasc Endovasc Surg Vol 29, June 2005order to exclude co-existing thromboses, the contral-
ateral limb and any other suspected site was assessed.
Clinical signs of PE or any complication were also
investigated.
Blood tests included full blood count, urea, creati-
nine, electrolytes, liver function tests and a clotting
profile. Patients under 40 years of age, those with
idiopathic thromboses and all those who presented
recurrence were also screened for thrombophilia.Evaluation of the primary outcomes
All clinically suspected DVTs were confirmed by
means of duplex scan ultrasonography. For this
purpose, a GE Logiq 500 Pro series (General Electric
Healthcare, Chalfont St Giles, UK) duplex scanner was
used with a 5.0–10.0 MHz (GE H40212LB Linear 739L)
linear probe and/or a 2.0–5.0 MHz (GE H40212LD
Convex C364) transducer, according to the depth of
the interrogated veins. We examined all venous
segments of both lower limbs as follows: the common
and external iliac veins, the common femoral vein, the
superficial femoral vein, the popliteal vein above and
below the knee joint and the infra-popliteal (anterior
tibial, posterior tibial, peroneal) veins. The superficial
venous system and the communicating veins were
also examined.
For the evaluation of DVT at baseline and scheduled
visits we utilized a quantitative duplex ultrasono-
graphic scoring system, adapted from the scoring
system originally described by Marder et al.27 (modi-
fied Marder score), shown in Table 2. We considered
this system as quite objective and reproducible
Table 2. Ultrasonographic quantification of deep vein thrombosis
(modified Marder score)27
Deep veins examined Score (points)*
Iliac 6
Common femoral 4
Superficial femoral 10
Popliteal 4
Anterior tibial 4 (2 points each)
Posterior tibial 6 (3 points each)
Peroneal 6 (3 points each)
* Total occlusion of the interrogated vein was given the maximum
score. Any segmental occlusion was assigned a lesser score
according to the extent of involvement.
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DVT, to 40 points, that indicate total occlusion of all
deep veins of the limb. A total score for the examined
limb was calculated by adding the scores of each
venous segment involved in the thrombotic process.
Each patient was given an initial score (before
initiation of therapy) and was monitored ultrasono-
graphically on subsequent visits (at 4 weeks, 3 months,
6 months and at 1 year) to quantitatively monitor the
evolution of thrombosis.
The presence of valve incompetence and reflux was
investigated at 1, 3, 6 and 12 months with duplex
scanning of the superficial, deep and perforating
veins. A standard technique was applied in all patients
by the same experienced ultrasonographer using the
same scanner. The examination of the venous system
was performed with the patient in the standing
position, holding onto a frame with most of the weight
placed on the opposite limb. The calf muscles were
manually compressed resulting in augmentation of the
venous flow and the sudden release of the distal
compression produced retrograde flow in the presence
of incompetence. Valve incompetence was considered
present when the valve closure time lasted more than
1 sec, following proximal or distal compression.Evaluation of secondary outcomes
Recurrence or progression of VTE was assessed by
duplex scan ultrasonography at the predefined by the
study protocol intervals, or at any time considered
necessary during the study period. Patients with
suspected recurrent DVT had an out-of-schedule
duplex ultrasound scan of lower limbs. Recurrent
DVT was defined as the presence of new thrombus in a
venous segment not found affected at the baseline
duplex ultrasound scan. Patients with clinically
suspected PE underwent a ventilation-perfusion lung
scan. The diagnosis of PE was made on the basis of
positive findings in the lung scan and, in case of
inconclusive results, on pulmonary arteriographyfindings or, in case of a fatal event, on the presence
of pulmonary artery emboli at autopsy.
The incidence of hemorrhagic complications during
the treatment period was also recorded and evaluated.
Bleeding was defined as major if it was overt and
associated with a drop in the hemoglobin level of
2 g/dl or more, if it required transfusion of two blood
units or more, if it was intracranial, intraspinal,
intraocular, pericardial, retroperitoneal or associated
with death or if the treatment had to be permanently
discontinued. Every other hemorrhagic event was
considered as minor bleeding.
Thrombocytopenia was defined as a platelet count
below 100,000/mm3 or a decrease of at least 50%
compared with the baseline value.
Every death that occurred throughout the study
period was recorded and the cause of each fatality was
documented.
The overall incidence of major events (DVT recur-
rence, PE, major bleeding, HIT and mortality) was
calculated and compared between the two treatment
groups.Follow-up
Following discharge, periodic visits were performed at
fixed intervals. Patients were instructed to attend the
vascular clinic at 4 weeks, 3 months, 6 months and at
1 year. Blood samples were collected at each visit for
the measurement of full blood count, liver function
tests and international normalized ratio (INR) values.
A thorough clinical examination as well as an
ultrasonographic assessment of the venous system of
both lower limbs was performed on all patients.
Moreover, they were instructed to refer to the hospital
immediately should symptoms or signs of recurrent
VTE or bleeding develop.Cost analysis
An assessment of the impact on direct costs to the
National Health System of the two treatment regimens
was performed. The analysis was made on the basis of
minimum hospitalization required to initiate and
monitor the treatment, laboratory tests performed
and the cost of drug therapy. The cost of tests equally
performed in both groups (laboratory tests and
ultrasound scans at regular intervals as defined by
the study protocol) was excluded from the analysis
and so was the cost of treatment of complications.Eur J Vasc Endovasc Surg Vol 29, June 2005
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Treatment compliance to acenocoumarol was assessed
by determining the INR at the predefined time
intervals during the treatment period. In the LMWH
group compliance was assessed by counting the
syringes returned at the follow-up visits.Interpretation of the diagnostic tests
Due to the nature of the treatment strategies, all
objective diagnostic tests were interpreted by special-
ists who were not involved in the study. The
Coagulation Unit staff, who had no knowledge of
whether the patients were participating in the study or
not, was responsible for monitoring the oral antic-
oagulation therapy. The Radiology Department staff,
who performed the serial duplex scans, was also
unaware of the treatment group to which each patient
belonged. Each patient was assigned with a score
according to the ultrasonographic results by two
experienced ultrasonographers (interobserver varia-
bility rZ0.76, p!0.001).Table 3. Baseline clinical characteristics of patients enrolled in the
study
Characteristic LMWH group OA group
Number of patients 50 52
Age (years)
Mean/median 59.0/58.5 58.2/60.5
Range 25–91 23–95
%40/41–70/R71 8/28/14 9/30/13Statistical analysis
Analysis was performed with the SPSS for Windows
(version 11.0; SPSS Inc, Chicago, IL, USA) statistical
package. A p value less than 0.05 was considered
significant. The Kolmogorov–Smirnov test was used to
test data for normal distribution. The tests applied
were Chi square and the Fischer’s exact test. Com-
parisons for non-parametric distributions were per-
formed with the Mann–Whitney U test. For multiple
comparisons, we set the significance at the level of
0.049 for two comparisons (e.g. first follow-up), down
to 0.045 for five comparisons (e.g. last follow-up)
(Kusuoka et al.).28BMI (Kg/m2)
Mean 26.3 25.9
Range 21.4–28.7 21.8–29.8
Sex (male/female) 19/31 22/30Results
Lower limb involved (right/left) 23/27 24/28
Etiology of DVT (%)
Idiopathic 22 24
Recent trauma/surgery 13 14
Immobilization 7 5
Malignancy 6 8
Oral contraceptives 2 1
Most proximal DVT level
Iliac vein 14 17
Common femoral vein 6 9
Superficial femoral vein 20 12
Popliteal vein 10 14
BMI, body mass index.Patients
One hundred and eight consecutive patients with
symptomatic proximal lower limb DVT, confirmed by
duplex ultrasound scan, fulfilling the study protocol
criteria were entered into the trial and randomized to
either the LMWH group (nZ55), or the OA group (nZ
53). Of these, six patients were excluded from the
analysis (five belonging to the LMWH and one to theEur J Vasc Endovasc Surg Vol 29, June 2005OA group) due to consent withdrawal before the
initiation of the assigned treatment.
Thus, for the final analysis (intention to treat
analysis before commencement of treatment) there
were 50 evaluable patients in the LMWH group and 52
in the OA group. There were 41 men and 61 women;
ages ranged from 23 to 95 years (mean age 58.6 years).
The clinical characteristics were similar in both groups
at the time of their enrollment into the study (Table 3).Clinical examination
In both groups, symptoms and clinical signs showed
quick response to the treatment and significant
improvement in the vast majority of patients over
the study time period. The improvement was gradual
throughout the 12-month study period, being notice-
able from the first re-evaluation after 1 month of
therapy. On completion of the surveillance period, the
clinical appearance was similar in the two groups:
edema (32% in the LMWH group versus 34.6% in the
OA group), local tenderness or pain (18 versus 15.4%,
respectively), skin changes (pigmentation, lipoderma-
tosclerosis, etc) (14 versus 19.2%) and venous ulcer
(three patients—5.8% in the OA group but no patient
in the LMWH group). No pathologic fractures or
symptoms of severe osteoporosis were reported
during the study period.
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Regular full blood counts showed no significant
alteration in the white blood count, red blood count,
hemoglobin and hematocrit throughout the study
period (results not presented).
Two patients (3.8%), both in the OA group,
developed HIT in the initial phase of their treatment
with UFH (day 4 and 6) (platelet count 45,000 and
70,000/mm3, respectively) and exited the study at that
point. No episode of tinzaparin-induced thrombocy-
topenia was reported.
In the OA group, calculated INR values were within
the target therapeutic range (2.0–3.0) in 67.2% of the
measurements, while in 13.6% of the tests INR was
found higher than 3.0 and in 19.1% lower than 2.0.Degree of thrombus regression
During the study period 461 color duplex ultrasound
scans were performed in 102 patients, 237 in the
LMWH group and 224 in the OA group.
For purposes of analysis we compared the median
values of the ultrasonographic scores between the
treatment groups at baseline, at 4 weeks, at 3 months,
at the end of the treatment period (6 months) and upon
conclusion of the observation phase (1 year).
All deep venous segments of each affected limb
were examined according to the protocol and seg-
mental scores were added to obtain the total score of
the limb at every specific examination. Total score
reduction, representing thrombus regression, was
noticed in both treatment groups and resulted con-
stant in all the follow-up assessments. However, a
more rapid recanalization was achieved with tinza-
parin, compared to OAs; these differences reached
significance at 3, 6 and 12 months (Table 4).
Patients were subsequently divided into four
subgroups, according to the most proximal throm-
bosed venous segment: iliac DVT, common femoral
DVT, superficial femoral DVT and popliteal DVT
subgroups. Comparisons of the total scores in these
subgroups are presented in Table 5, showing that theTable 4. Effect of the two treatments on the evaluation of the overall
Time (months) 0 1
Overall thrombosis
Marder score
median (inter-
quartile range)
LMWH group (nZ50) 13.5 (10–19.25) 11 (8.
OA group (nZ52) 14 (10.25–18) 12 (9–
p value 0.668NS 0.228
The results are expressed as median ultrasonographic modified Marde
anticoagulant; NS, not significant.
* Statistically significant.advantage of tinzaparin over acenocoumarol was not
constantly significant in all subgroups. Results ranged
from a non-statistically significant difference at all
times in patients with iliac thrombosis, to a constant
significance during the study period in those with
superficial femoral thrombosis.
The above findings correspond with results deriv-
ing from the study of thrombus evolution in each
individual deep vein. The scores of the affected
proximal deep venous segments (iliac, common
femoral, superficial femoral and popliteal veins) over
time, representing rate of recanalization in each vein
separately, were compared between the two groups
(Table 6). The comparison was also in favor of LMWH
at all times, but never reached statistical significance in
the iliac vein, while maintaining significant difference
from the third month onwards in the superficial
femoral and popliteal veins.Evaluation of venous reflux
The affected limbs were examined for the presence of
superficial, perforating and deep venous reflux and for
the development of valve incompetence as part of the
routinely performed ultrasound scannings at 1, 3, 6
and 12 months.
Reflux patterns detected at all assessments, overall
and considering each venous segment separately,
worsened equally in time but did not differ signifi-
cantly in both treatment regimes, although there was a
trend in favor of the tinzaparin group (Table 7).Venous thromboembolic recurrences
During the treatment period (initial 6 months) two
cases of recurrent DVT in the LMWH group (4%) and
three cases in the OA group (5.8%, pZnon-significant
(ns)) were identified. All were extensions of known
thromboses.
Overall, in the whole period of the study (1 year),
DVT recurrence was observed in three of the 50
patients treated with tinzaparin (6%) and in five of therecanalization
3 6 12
5–15.5) 9 (7–10) 6.5 (4–9) 5 (3–7)
16) 10 (8–15) 8 (6–12) 7 (5–10)
NS 0.017* 0.013* 0.011*
r DVT score. LMWH, low molecular weight heparin; OA, oral
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Table 6. Regression of thrombus size in individual proximal venous segments (iliac, common femoral, superficial femoral, popliteal vein)
Time (months) 0 1 3 6 12
Iliac vein
Marder score
median–mean
(interquartile
range)
LMWH group (nZ14) 3–2.86 (2–4) 2–2.46 (2–3) 2–2.15 (1.5–3) 1–1.33 (1–2) 1–1.33 (1–2)
OA group (nZ17) 3–2.71 (2–4) 2.5–2.5 (2–3) 2–2 (2–2) 1.5–1.5 (1–2) 1–1.33 (1–2)
p value 0.725NS 0.836NS 0.717NS 0.475NS 1.000NS
Common femoral vein
Marder score
median–mean
(interquartile
range)
LMWH group (nZ20) 3.5–3.05 (2–4) 3–2.75 (1.25–4) 2–2.35 (1–4) 1–1.73 (1–3) 1–1.57 (1–2.25)
OA group (nZ26) 3–3 (2–4) 3–2.91 (2–4) 3–2.67 (2–3.5) 2–2.5 (2–3) 2–2.47 (2–3)
p value 0.850NS 0.682NS 0.396NS 0.025* 0.008*
Superficial femoral vein
Marder score
median–mean
(interquartile
range)
LMWH group (nZ40) 6–5.7 (3.25–8) 4–4.87 (3–8) 4–4 (2–6) 3–3.44 (2–5) 3–3.12 (2–5)
OA group (nZ38) 6.5–6.03 (4–8) 6–5.67 (4–7.5) 5–5.13 (3.25–6) 5–4.71 (3–6) 4–4.12 (3–5.25)
p value 0.671NS 0.162NS 0.035* 0.013* 0.032*
Popliteal vein
Marder score
median–mean
(interquartile
range)
LMWH group (nZ46) 4–3.37 (3–4) 3–3.05 (2–4) 2–2.39 (2–3) 2–2 (1–3) 1–1.59 (1–2)
OA group (nZ51) 4–3.14 (2–4) 3–3.02 (2–4) 3–2.9 (2–4) 2–2.49 (2–3) 2–2.06 (1–3)
p value 0.359NS 0.939NS 0.021* 0.027* 0.018*
The results are expressed as median–mean (interquartile range) ultrasonographic modified Marder DVT score for the specific vein. In italics,
mean values; in brackets, interquartile range; DVT, deep venous thrombosis; LMWH, low molecular weight heparin; OA, oral anticoagulant;
NS, not significant.
* Statistically significant.
Table 5. Effect of the two treatments on the evaluation of recanalization according to the most proximal DVT level (iliac, common
femoral, superficial femoral, popliteal vein)
Time (months) 0 1 3 6 12
Iliac DVT
Marder score
median (inter-
quartile range)
LMWH group (nZ14) 20 (9.2–26.5) 19 (9–22.25) 10 (8–18.5) 8.5 (6–13.5) 6.5 (4.7–11.2)
OA group (nZ17) 18 (13.5–23) 16 (11.25–22) 14 (9.5–18) 11 (6.5–14.7) 10 (7–15)
p value 0.921NS 0.890NS 0.576NS 0.454NS 0.137NS
Common femoral DVT
Marder score
median (inter-
quartile range)
LMWH group (nZ6) 17 (12.3–21) 13 (12–16.25) 9 (8–10.25) 7 (6–12) 5 (4–6.5)
OA group (nZ9) 17 (12–19.5) 14.5 (11–18.5) 13 (10–16) 10 (7–14) 7 (6–12)
p value 0.813NS 0.515NS 0.021* 0.278NS 0.085NS
Superficial femoral DVT
Marder score
median (inter-
quartile range)
LMWH group (nZ20) 13 (11–17) 10 (9–12) 9 (6.7–10.2) 7 (5–8) 5 (3–6.5)
OA group (nZ12) 14 (11–17.5) 12 (11–16) 11 (9–17) 9 (7–14.5) 7 (5.25–9.5)
p value 0.725NS 0.021* 0.015* 0.014* 0.020*
Popliteal DVT
Marder score
median (inter-
quartile range)
LMWH group (nZ10) 8 (7.8–11) 8 (5–9.5) 6 (5–7) 3 (1.5–5) 3 (1.5–5)
OA group (nZ14) 9 (8–12) 8.5 (7.7–10.2) 7.5 (6–10) 6 (5–7.5) 4 (3–5.5)
p value 0.406NS 0.299NS 0.124NS 0.009* 0.237NS
These patients may have had more distal DVT. The results are expressed as median (interquartile range) ultrasonographic modified Marder
DVT score of all the involved veins. In brackets, interquartile range; DVT, deep venous thrombosis; LMWH, low molecular weight heparin;
OA, oral anticoagulant; NS, not significant.
* Statistically significant.
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Table 7. Segmental vein reflux score, as identified by color duplex scanning at 1, 3, 6 and 12 months, in the two treatment groups
Reflux in Superficial venous system Communicating veins Deep venous system Total
Time
(months)
OA LMWH p OA LMWH p OA LMWH p OA LMWH p
Number of segments
1 28 23 NS 9 8 NS 7 7 NS 44 38 NS
3 26 23 NS 9 7 NS 5 8 NS 40 38 NS
6 28 24 NS 14 12 NS 36 36 NS 78 72 NS
12 28 23 NS 15 13 NS 44 42 NS 87 78 NS
Percentages
1 29.8% 23.5% NS 19.1% 16.3% NS 5.0% 4.8% NS 15.6% 12.9% NS
3 28.9% 24.5% NS 20.0% 14.9% NS 3.7% 5.7% NS 14.8% 13.5% NS
6 28.0% 20.7% NS 31.7% 23.9% NS 17.1% 18.8% NS 23.2% 20.3% NS
12 37.2% 25.0% NS 38.5% 26.1% NS 42.7% 26.8% NS 40.2% 26.1% NS
Lower limb venous system divided into six segments: iliofemoral, femoropopliteal, infrapopliteal, perforators, LSV and SSV systems.
LMWH, low molecular weight heparin; OA, oral anticoagulant; LSV, long saphenous vein; SSV, short saphenous vein; NS, not significant.
LMWH Tinzaparin vs Acenocoumarol in the Long-term DVT Treatment 64552 patients treated with acenocoumarol (9.6%, pZns)
(Table 8). All DVT recurrences were objectively
documented with duplex ultrasound scanning.
One single incidence of symptomatic PE was diag-
nosed in a patient assigned to OAs, which resulted
fatal. It occurred in a 73-year-old woman with ilio-
femoral thrombosis, on the 11th day of treatment and
was confirmed at post-mortem examination.Hemorrhagic complications
There were no significant differences in bleeding
complications in the two groups.
In the LMWH group two major bleeds (4%)
occurred during the second and third month of
treatment, the first of which was fatal. Minor hemor-
rhage was reported in three other patients (6%) during
the treatment period. In addition, almost all patients
receiving tinzaparin developed multiple subcu-
taneous hematomas and bruises at injections sites,
which produced minor discomfort and resolved
uneventfully within 2 weeks from completion of
treatment.
In the OA group four patients (7.7%, pZns) had
major bleeds, one of them fatal. Episodes of minor
bleeding were identified in three patients (5.8%,
pZns).
Table 8 shows the incidence of hemorrhagic
complications in both groups.Mortality
During the 12-month period of the study a total of
seven deaths (6.9%) occurred (Table 8).
In the tinzaparin group the overall mortality was
4% (two deaths). One death followed an episode of
major hemorrhage (related mortality 2%) and the
other occurred on the 9th day of the treatment in a78-year-old man with iliofemoral venous thrombosis
who developed a non-hemorrhagic stroke (unrelated
mortality 2%).
In the acenocoumarol group five patients (9.6%,
pZns) died. Mortality was related to thromboembol-
ism or treatment complications in two cases (PE and
major hemorrhage) (related mortality 3.8%, pZns).
The three remaining deaths were unrelated to throm-
bosis (unrelated mortality 5.8%, pZns) and occurred
due to progression or complication of those patients’
initial disease state. Two of those deaths occurred
while patients were receiving the assigned therapy
and one during the 6-month surveillance period.Incidence of major events
In the analysis of the data on the intention to treat basis
the overall incidence of major events was significantly
lower in the LMWH group [seven events (14%) versus
17 events (32.7%); pZ0.0354] (Table 8).Cost analysis
According to the study protocol only patients assigned
to conventional therapy were hospitalized. Therefore,
a cost analysis was performed for these subjects on the
basis of minimum in-patient days, laboratory tests
performed for treatment monitoring and cost of
medications. The LMWH group was monitored at
the same time intervals and subjected to equally
performed laboratory tests (except INR tests) as the
OA group. We considered the cost of the tinzaparin
injections of 0.7 ml at V13.515 (euros), corresponding
to the mean body weight of the LMWH group, as the
average therapeutic dosage of an adult patient with
DVT.
The mean cost of an in-patient day in our institution
is estimated at V298.6 per occupied hospital bed,Eur J Vasc Endovasc Surg Vol 29, June 2005
Table 8. Incidence of secondary outcomes in the two treatment groups during the study period
Group Complication
category
Patients Complication Day
occurred
Initial disease Age Sex
LMWH Recurrent DVT 3 (6%) Symptomatic iliac DVT 68 Superficial femoral DVT 83 f
Symptomatic common femoral
DVT
115 Superficial femoral DVT 75 m
Asymptomatic superficial femoral
DVT
365* Popliteal DVT, breast cancer 53 f
Major bleeding 2 (4%) Upper gastrointestinal bleeding,
acute myocardial infarction, death
41 Superficial femoral DVT 72 f
Massive rectal bleeding 84 Superficial femoral DVT, sigmoid
colon cancer recurrence
63 m
Minor bleeding 3 (6%) Hematuria 52 Iliac DVT 66 m
Gingival bleeding 79 Superficial femoral DVT 58 f
Hematuria 127 Iliac DVT 87 f
Death 2 (4%) Unrelated death 9 Iliac DVT, atrial fibrillation,
embolic stroke
78 m
Related death 43 Superficial femoral DVT, upper
gastrointestinal bleeding, acute
myocardial infarction
72 f
OAs Recurrent DVT 5 (9.6%) Symptomatic superficial femoral
DVT
52 Popliteal DVT 53 f
Asymptomatic common femoral
DVT
91* Superficial femoral DVT 27 m
Symptomatic common femoral
DVT
147 Superficial femoral DVT 60 f
Symptomatic iliac DVT 211 Common femoral DVT 91 f
Symptomatic iliac DVT 289 Iliac DVT 69 f
PE 1 (1.9%) Symptomatic PE, death 11 Iliac DVT 73 f
Major bleeding 4 (7.7%) Upper gastrointestinal bleeding 15 Superficial femoral DVT 68 f
Retroperitoneal hematoma 23 Common femoral DVT 62 m
Severe hematuria 67 Common femoral DVT, bladder
carcinoma
75 f
Massive hemoptysis, death 136 Iliac DVT, prostate cancer, lung
metastases
58 m
Minor bleeding 3 (5.8%) Melena 66 Iliac DVT 70 f
Melena 98 Popliteal DVT 42 m
Hematuria 141 Superficial femoral DVT 61 f
HIT 2 (3.8%) Thrombocytopenia 4 Iliac DVT 63 m
Thrombocytopenia 6 Iliac DVT 50 f
Death 5 (9.6%) Related death 13 Iliac DVT, symptomatic PE 73 f
Unrelated death 59 Iliac DVT, uterine cancer 54 f
Unrelated death 107 Superficial femoral DVT, acute
myocardial infarction
65 m
Related death 136 Iliac DVT, prostate cancer, lung
metastases, hemoptysis
58 m
Unrelated death 253 Iliac DVT, embolic stroke 80 f
DVT, deep venous thrombosis; PE, pulmonary embolism; HIT, heparin-induced thrombocytopenia; m, male; f, female.
* Asymptomatic DVT recurrences identified at regular follow-up examination.
M. E. Daskalopoulos et al.646including all hospital and staff expenses. The mean
total hospitalization cost per day, estimated atV383.96,
was calculated on the basis of the cost of the in-patient
day plus the cost of any additional material required
for drug therapy administration and monitoring (i.e.
infusion pumps, intravenous fluid devices, intrave-
nous catheters, syringes, swabs, etc).
Patients initially treated with UFH and switched to
OA required a minimum of five in-patient days. A
mean of 12 INR tests was required to monitor
anticoagulation efficacy in the acenocoumarol group.
The cost of the two treatment regimens is outlined in
Table 9. A comparable total cost was estimated slightlyEur J Vasc Endovasc Surg Vol 29, June 2005in favor of tinzaparin, mainly due to the significant cut
in hospitalization costs achieved by the LMWH.
The number of major events requiring hospitaliz-
ation was significantly lower in the LMWH group. The
cost of these hospitalizations was not estimated;
however, it is obvious that a substantial additional
cost would be attributed to the OA group.Discussion
This open-label prospective randomized clinical trial
evaluates the effectiveness and safety of LMWH
Table 9. Cost analysis comparing LMWH and conventional
therapy
Item Cost per
item
LMWH
group
OA group
Hospitalization* – V1919.8
Lab tests (in-hospital treatment)
FBC V24.44 – !5ZV122.2
aPTT V24.44 – !6ZV146.64
PT V20.63 – !2ZV41.26
In-hospital medications† – V15.58
Total in-hospital cost – V2245.48
Lab tests (outpatient treatment)
PT V20.63 – !12ZV247.56
Six-month medications‡ V2432.7 V11.52
Total outpatient cost V2432.7 V259.08
Total cost V2432.7 V2504.56
* Hospitalization cost was calculated on the basis of the cost of an
in-patient day (V298.6 per day) plus the cost of any additional
material required for drug therapy institution and monitoring (i.e.
infusion pumps, intravenous fluid devices, intravenous catheters,
syringes, swabs, etc). Total cost V383.96 per day for a minimum of
5 days.
† In-hospital medications, UFH (Heparin/Leo) (25,000 IU/5 ml-
vial: V2.86) 5!V2.86ZV14.3. Acenocoumarol (Sintrom/Novartis)
20 tab 4 mg: V1.28.
‡ Six-month outpatient medications: tinzaparin (Innohep/Leo)
(2!14,000 anti Xa IU/0.7 ml inject. solution: V27.03) 90!V27.03Z
V2432.7. Acenocoumarol (Sintrom/Novartis) (20 tab 4 mg: V1.28)
9!V1.28ZV11.52.
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duration of long-term DVT therapy in comparison
with classic oral anticoagulation therapy.
In recent years LMWHs have extensively replaced
UFH in both thromboprophylaxis and initial treatment
of VTE. Currently, research interest is focused on the
evaluation of LMWHs in the long-term treatment of
DVT and PE in different patient populations.
Although results from several clinical trials are
available, a uniform clinical conclusion extracted from
these studies based on meta-analyses would be
inappropriate due to the fact that these studies
compare therapies of different duration and dosages
using various LMWHs, which are known to be distinct
non-interchangeable compounds.29
Tinzaparin sodium is a LMWH administered once
daily in weight adjusted doses, by subcutaneous
injection, with no need for laboratory monitoring.30–35
All patients in our study were randomized immedi-
ately after the ultrasonographic confirmation of their
DVT, prior to administration of any anticoagulant
therapy, in order to obtain results that could be clearly
attributed to each treatment regimen.
A double blind study was not feasible due to the
different route of administration of the two drugs and
the need for regular dose adjustment in the OA group.
To minimize any possible bias, objective tests and data
analysis were performed blindly. The participants in
the two groups were comparable at the study onsetregarding demographic characteristics, predisposing
factors, location of thrombi and extent of the venous
thrombosis.
The frequency of recurrent VTE (recurrent DVT or
PE) showed no statistically significant difference
between the tinzaparin and acenocoumarol group,
suggesting that LMWHs are equally effective as OAs
in the long-term DVT treatment, in agreement with the
majority of the published studies.17,18,21–23,36 DVT
recurrences in the two groups were similarly distrib-
uted both in the treatment and surveillance periods,
while only one episode of symptomatic PE was
identified during the study period. Since, routine
duplex scans were performed for each patient on five
fixed occasions it is unlike that any asymptomatic DVT
recurrence was overlooked. On the contrary, episodes
of silent PE may have remained undetected since no
routine PE diagnostic test was performed and only
clinically suspected cases were further investigated.
Thrombus volume regression is considered as
another index of the effectiveness of anticoagulation
treatment. The adoption of a reproducible scoring
system, originally created for venographic evaluation
of thrombosis, allowed us to quantify the ultrasono-
graphic findings of thrombi evolution. The available
ultrasound scanner technology enabled us to obtain
high-resolution color duplex images of the venous
system, as detailed as those acquired through veno-
graphy though in a less invasive and much safer way.
Comparing ultrasonographic scores deriving from
the two study groups, the gradual reduction over time
that reflects thrombus regression resulted more pro-
minent in the LMWH group. These findings suggest
that tinzaparin performs better than the combination
of UFH and acenocoumarol in the resolution of
thrombosis. In fact, both therapeutic regimens were
proved effective in preventing progression of thrombi
and allowing recanalization of the affected veins.
However, thrombus lysis appears earlier and more
extensively in the LMWH than in the OA group. The
difference reaches statistical significance at 3, 6 and 12
months and could be due to a direct or indirect
fibrinolytic effect of LMWHs.37–39
When considering the four patient subgroups, the
advantage of tinzaparin in terms of thrombus
regression does not appear constantly significant. In
fact, results ranged from a non-statistically significant
difference at all times in patients with iliac thrombosis,
to a significance verified constantly throughout the
study in those with superficial femoral thrombosis.
Routine ultrasound scans performed at 1, 3, 6 and
12 months verified the presence of reflux and valve
incompetence. We deliberately omitted examination of
venous insufficiency at the initial duplex scan in theEur J Vasc Endovasc Surg Vol 29, June 2005
M. E. Daskalopoulos et al.648presence of fresh clots. We found that earlier recana-
lization induced by tinzaparin did not result in less
valve incompetence, as detected reflux overall and in
the affected venous segments separately worsened
equally in time between the two groups. Reflux in
superficial, deep and perforating veins was not
significantly different when comparing the two treat-
ments. Others22 demonstrated a significantly lower
rate of reflux in the communicating veins of patients
treated with LMWH.
In the published literature eight randomized trials
(Table 10) compared a LMWH against OAs in the long-
term treatment of venous thrombosis. These studies
involved several LMWHs (enoxaparin, dalteparin,
nadroparin), administered according to various pro-
tocols, with duration of treatment mainly of 3 months.
Since, the majority of proximal DVT events require a 6-
month therapy, we excluded from our study DVTs
restricted to the infrapopliteal segments that might
respond to a shorter therapy. Only two randomized
trials apply a therapeutic schedule of 6-month dur-
ation. Lo´pez-Beret et al.22 compared nadroparin withTable 10. Randomized studies comparing LMWH versus OAs in the
Author Patients
enrolled
(N)
Assessment
method
LMWH
treatment
protocol
Duration of
therapy
(months)
Ou
VT
rec
Pini et al.
1994
187 ACV, SGP Enoxaparin
4000 anti Xa
IU o.d.
3 6
Das et al.
1996
105 ACV Dalteparin
5000 anti Xa
IU o.d.
3 5
Lopaciuk
et al. 1999
193 ACV Nadroparin
85 anti Xa
IU/Kg o.d.
3 2
Gonzalez-
Fajardo
et al. 1999
165 ACV Enoxaparin
4000 anti Xa
IU o.d.
3 8
Veiga et al.
2000*
100 ACV Enoxaparin
4000 anti Xa
IU o.d.
3 2
Lopez-Ber
et al. 2001
158 U/S Nadropar-
ine 0.1ml/
10 Kg b.d.
3–6 0
Meyer et al.
2002†
146 ACV, U/S Enoxaparin
1.5 mg/Kg
o.d.
3 3
Lee et al.
2003†
676 ACV, U/S Dalteparin
150 anti Xa
IU/Kg o.d.
6 27
Current
study 2003
102 U/S Tinzaparin
175 anti Xa
IU/Kg o.d.
6 2
LMWH, low molecular weight heparin; OAs, oral anticoagulants; VTE
SGP, strain gauge plethysmography; o.d., once daily; U/S, color duple
* Study involved elderly patients only.
† Studies involved cancer patients exclusively.
Eur J Vasc Endovasc Surg Vol 29, June 2005acenocoumarol; the LMWH was administrated for 6
months only in selected patients with persistent risk
factors for thrombosis or idiopathic DVT, halving the
initial dosage of nadroparin during the last 3 months
of treatment. Lee et al.24 studied the efficacy and safety
of dalteparin compared to a coumarin derivative
exclusively in patients with cancer who had devel-
oped proximal DVT or PE. Results from both trials
were in favor of the LMWH used.
The latest systematic review of the literature by the
Cochrane Collaboration40 concluded that treatment
with LMWHs is significantly safer than treatment with
OAs. Our results are in accordance with this state-
ment; we found a significantly lower incidence of total
major events (complications and mortality) in favor of
the tinzaparin group. However, no statistically signifi-
cant difference was found between the two groups,
regarding either major and minor hemorrhagic com-
plications or HIT, nor related or unrelated fatal events,
probably because of the small sample examined.
Despite the satisfactory compliance of all patients in
wearing elastic graduated compression stockings on along-term treatment of venous thromboembolism
tcome events (LMWH versus OAs) Duration of
follow-up
(months)
VTE
recurrence
E
urrence
Bleeding
compli-
cations
Deaths LMWH OAs
4 4 12 4 3 9 10 4
2 0 5 1 3 – – –
7 4 7 2 2 9 5 2
19 1 8 1 0 9 3 3
1 1 6 3 1 9 6 5
3 3 3 7 6 6 2 4
2 5 12 8 17 3 3 0
53 19 12 130 136 – – –
3 2 4 2 4 6 1 2
, venous thrombo-embolism; ACV, ascending contrast venography;
x ultrasound; b.d., twice daily.
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during the study period was edema in the affected
lower limb; this was similar in both groups. Through-
out the trial venous ulceration occurred in three
patients, all belonging to the OA group. However,
the 12-month follow-up period is too short to reflect
the true development of clinical post-thrombotic
syndrome.
There is a lack of studies regarding cost comparison
in patients treated for DVT.41 Among the randomized
trials performed in the past involving a LMWH versus
OAs, an assessment of the cost was performed only in
the report of Das et al.18 They found that a cost saving
of as much as £900 (sterling pounds) per patient could
be achieved since subjects allocated to receive LMWH
could be discharged 3 days earlier than those receiving
warfarin. In our study, the minimum duration of the
initial hospitalization for the OA group was 5 days.
Although there is no absolute consensus regarding the
optimal duration of in-hospital treatment of DVT
patients, our results indicate that the burden of health
care resources outweighs the cost of any outpatient
treatment. Liebowitz42 estimated that more than $9000
(US dollars) in charges would have been saved for
every patient receiving outpatient treatment with
enoxaparin sodium. Moreover, Harrison et al.13 intro-
duced patient’s satisfaction as a new parameter. They
reported that 91% of their patients were ‘very pleased’
to be treated at home and more than 80% of the study
participants were ‘satisfied’ or ‘very satisfied’ with
self-injection.
In conclusion, the current trial suggests that a single
fixed daily dose of the LMWH tinzaparin, adminis-
tered on an outpatient basis without laboratory
monitoring for a period of 6 months, is at least as
effective and safe as the treatment with UFH followed
by OAs and could be an alternative to the conventional
long-term DVT secondary prophylaxis. The 6-month
duration of treatment was associated with a signifi-
cantly lower incidence of major events in the LMWH
group and ensured the advantage of tinzaparin over
acenocoumarol regarding recanalization, achieved
at 3 months, without compromising patients’ satisfac-
tory compliance with the once daily subcutaneous
injection.Acknowledgements
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